This is an international site for Tasigna® (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the U.S. I am a U.S. resident I am a patient outside the U.S.
Print Text Size Glossary Summary of Product Characteristics Safety Information U.S. Residents

This site is intended for Healthcare Professionals outside the U.S.

Mechanism of Action
Interactive Game

INTERACTIVE GAME

In this interactive game you will create your own TKI by moving the nodes up and down to match the Bcr-Abl binding pocket.

TASIGNA Interactive Game
TASIGNA Interactive Game
Click Here to Play the Game>>

TASIGNA delivered the deepest measurable reductions in Bcr-Abl levels in more patients with newly diagnosed Ph+ CML than imatinib.4

TASIGNA demonstrated superior efficacy head-to-head vs. imatinib in patients with newly diagnosed Ph+ CML.4

Loading the player ...